Friday, December 18, 2020 6:03:44 AM
https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-positive-initial-regeneron-antibody-cocktail-results-in-non-hospitalized-patients-with-covid-19-301195460.html
A goal is a dreams deadline...what is your goal?
´¯`·.¸¸.·´¯`·.¸ ><((((((º>
`·.¸¸.·´¯`·.¸¸.·´¯`·.¸ ><((((º>
Recent REGN News
- Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 11/15/2024 05:59:51 AM
- Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH • GlobeNewswire Inc. • 11/13/2024 12:00:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 09:03:11 PM
- Regeneron Announces Investor Conference Presentations • GlobeNewswire Inc. • 11/11/2024 09:05:00 PM
- Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis • GlobeNewswire Inc. • 11/06/2024 06:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 09:23:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2024 08:38:27 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 10/31/2024 08:33:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/31/2024 11:16:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 11:10:23 AM
- Regeneron Reports Third Quarter 2024 Financial and Operating Results • GlobeNewswire Inc. • 10/31/2024 10:30:00 AM
- Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI • GlobeNewswire Inc. • 10/24/2024 12:00:04 PM
- Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema • GlobeNewswire Inc. • 10/18/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 11:00:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2024 08:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2024 08:02:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/01/2024 08:13:23 PM
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD • GlobeNewswire Inc. • 09/27/2024 01:35:08 PM
- Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) • GlobeNewswire Inc. • 09/27/2024 11:00:04 AM
- Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 • GlobeNewswire Inc. • 09/26/2024 08:05:00 PM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old • GlobeNewswire Inc. • 09/20/2024 11:45:00 AM
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) • GlobeNewswire Inc. • 09/13/2024 04:15:28 PM
- EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile • GlobeNewswire Inc. • 09/11/2024 11:00:46 AM
- Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer • GlobeNewswire Inc. • 09/09/2024 09:00:00 PM
- Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO • GlobeNewswire Inc. • 09/09/2024 11:00:17 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM